Our data demonstrates that patients with adenocarcinomas of the lung who are TTF-1 negative have at least a 96% chance of being EGFR wild type when the prevalence of EGFR mutations is approximately 15%. This evidence concerns the gene EGFR and lung adenocarcinoma.